Posted by Michael Wonder on 14 Nov 2018
ICER report finds biologic treatments for uncontrolled asthma would require more than a 50% price discount to reach common thresholds for cost-effectiveness
13 November 2018 - Midwest CEPAC to vote on the overall value of treatments during 29 November public meeting.
The ICER today released an Evidence Report assessing the comparative clinical effectiveness and value of biologic treatments for asthma associated with type 2 inflammation and/or allergic asthma.
The report focuses on dupilumab (Dupixent, Sanofi/Regeneron), omalizumab (Xolair, Genentech/Novartis), mepolizumab (Nucala, GlaxoSmithKline), reslizumab (Cinqair, Teva), and benralizumab (Fasenra, AstraZeneca). ICER previously reviewed mepolizumab for its use in severe eosinophilic asthma and dupilumab for its use in atopic dermatitis.
"All five biologics modestly reduce asthma exacerbations and improve daily quality of life," said David Rind, MD, ICER's Chief Medical Officer. "However, the treatments' net prices appear to be far out of alignment with these incremental clinical benefits, and the entire therapy class would need to see price discounts of at least 50% to reach commonly cited thresholds for cost-effectiveness."
